Pirotte J, Borlée-Hermans G, Boniver J, Godon J P
Hôpital de Bavière, Division of Gastroenterology, Liège, Belgium.
Biomed Pharmacother. 1988;42(1):55-9.
Serum beta 2-microglobulin (beta 2 mu), a reliable marker of T-cell activation, was measured in 25 patients with chronic post-transfusion non A non B (NANB) liver disease and in 21 patients with HBsAg positive chronic liver disease. beta 2 mu levels were elevated in NANB patients when compared with controls but not in comparison with the HBsAg carriers. In NANB patients, beta 2 mu concentrations were significantly correlated with serum IgG (P less than 0.001) and with circulating immune complex activity, assessed by the 125IClq binding test (P less than 0.01). These findings suggest that, in addition to T-cells, the B-cells contributed also to the beta 2 mu production. Patients with "active disease" (chronic active hepatitis and active cirrhosis) had significantly higher beta 2 mu levels (P less than 0.001) than did those with "inactive disease" (chronic persistent hepatitis and inactive cirrhosis). This relation of serum beta 2 mu concentrations and histological activity was also observed in the HBsAg carriers and suggests that the course of post-transfusion NANB chronic hepatitis could be determined by host's immune response rather than by a direct effect of the virus.
检测了25例慢性输血后非甲非乙型（NANB）肝病患者和21例HBsAg阳性慢性肝病患者血清中的β2微球蛋白（β2μ），它是T细胞活化的可靠标志物。与对照组相比，NANB患者的β2μ水平升高，但与HBsAg携带者相比则未升高。在NANB患者中，β2μ浓度与血清IgG显著相关（P<0.001），并与通过125I Clq结合试验评估的循环免疫复合物活性相关（P<0.01）。这些发现表明，除T细胞外，B细胞也参与了β2μ的产生。“活动性疾病”（慢性活动性肝炎和活动性肝硬化）患者的β2μ水平显著高于“非活动性疾病”（慢性持续性肝炎和非活动性肝硬化）患者（P<0.001）。在HBsAg携带者中也观察到血清β2μ浓度与组织学活性之间的这种关系，这表明输血后NANB慢性肝炎的病程可能由宿主的免疫反应而非病毒的直接作用决定。
